4.8 Article

Bilirubin nanoparticle preconditioning protects against hepatic ischemia-reperfusion injury

期刊

BIOMATERIALS
卷 133, 期 -, 页码 1-10

出版社

ELSEVIER SCI LTD
DOI: 10.1016/j.biomaterials.2017.04.011

关键词

Bilirubin; Nanoparticles; Ischemia-reperfusion injury; Liver transplantation; Reactive oxygen species; Anti-inflammatory therapy

资金

  1. Global Research Laboratory grant through the National Research Foundation of Korea (NRF) - Ministry of Science, ICT & Future Planning [2015045887]
  2. Global Ph.D. Fellowship through the National Research Foundation of Korea (NRF) - Ministry of Science, ICT & Future Planning [2014H1A2A1019986]
  3. National Research Foundation of Korea [2014H1A2A1019986, 2012K1A1A2045436] Funding Source: Korea Institute of Science & Technology Information (KISTI), National Science & Technology Information Service (NTIS)

向作者/读者索取更多资源

Hepatic ischemia-reperfusion injury (IRI) remains a major concern in liver transplantation and resection, despite continuing efforts to prevent it. Accumulating evidence suggests that bilirubin possesses antioxidant, anti-inflammatory and anti-apoptotic properties. However, despite obvious potential health benefits of bilirubin, its clinical applications are limited by its poor solubility. We recently developed bilirubin nanoparticles (BRNPs) consisting of polyethylene glycol (PEG)-conjugated bilirubin. Here, we sought to investigate whether BRNPs protect against IRI in the liver by preventing oxidative stress. BRNPs exerted potent antioxidant and anti-apoptotic activity in primary hepatocytes exposed to hydrogen peroxide, a precursor of reactive oxygen species (ROS). In a model of hepatic IRI in mice, BRNP preconditioning exerted profound protective effects against hepatocellular injury by reducing oxidative stress, pro-inflammatory cytokine production, and recruitment of neutrophils. They also preferentially accumulated in IRI-induced inflammatory lesions. Collectively, our findings indicate that BRNP preconditioning provides a simple and safe approach that can be easily monitored in the blood like endogenous bilirubin, and could be a promising strategy to protect against IRI in a clinical setting. (C) 2017 Elsevier Ltd. All rights reserved.

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.8
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

暂无数据
暂无数据